Zimmer Biomet declares $0.24 quarterly dividend By Investing.com
Zimmer Biomet Holdings, Inc. announced a quarterly cash dividend of $0.24 per share for Q2 2026, payable on July 31, 2026. This follows strong financial results for Q1 2026, where the company exceeded earnings and revenue forecasts, though analysts have adjusted price targets due to perceived risks. The company also increased its 2026 share repurchase plan to $1 billion.
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings, Inc. announced that its Board of Directors has approved a quarterly cash dividend of $0.24 per share for the second quarter of 2026. This dividend is payable on or about July 31, 2026, to stockholders of record as of the close of business on June 25, 2026. The company is a global medical technology leader focusing on improving health through innovative products and integrated digital and robotic technologies.
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings, Inc. announced that its Board of Directors has approved a quarterly cash dividend of $0.24 per share for the second quarter of 2026. This dividend is payable on or about July 31, 2026, to stockholders of record as of June 25, 2026. The company is a global medical technology leader focused on maximizing mobility and improving health through innovative products.
Zacks Industry Outlook Highlights Electromed, Globus Medical and Intuitive Surgical
This Zacks Industry Outlook highlights Electromed (ELMD), Globus Medical (GMED), and Intuitive Surgical (ISRG) as key players poised to thrive in the medical instruments industry, driven by the increasing adoption of generative AI. The article details how AI is transforming medical diagnostics, surgeries, and drug development, despite industry challenges such as global economic slowdowns and inflation. It also discusses M&A trends and the current market valuation for medical instrument stocks.
Zimmer Biomet Holdings, Inc. $ZBH Stake Cut by Heritage Investors Management Corp
Heritage Investors Management Corp reduced its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 8.3% in the fourth quarter, selling 12,149 shares. This leaves them with 133,845 shares valued at approximately $12.0 million. Despite mixed institutional activity and a consensus "Hold" rating from analysts, Zimmer Biomet reported strong quarterly results, exceeding EPS and revenue expectations.
Zimmer Biomet Holdings, Inc. Stock 12‑Month Price Target Cut to $96.45, Implies 13% Upside
Analyst estimates for Zimmer Biomet Holdings, Inc. (ZBH) have led to a reduced 12-month average price target of $96.45, down from $97.33, implying a 13% potential upside from its May 21 closing price. The consensus rating from 30 analysts is now "Hold," with a breakdown of 9 Buys, 19 Holds, and 2 Sells. This information provides an updated outlook for investors considering ZBH.
Zimmer Biomet stock (US98956P1021): earnings and buyback update keep focus on implants
Zimmer Biomet recently reported quarterly results, reaffirmed its outlook, and increased its fiscal 2026 share repurchase expectations to $1 billion. The company's stock performance remains heavily influenced by the demand for hip and knee replacement systems, reflecting the sensitivity to elective procedures and hospital purchasing trends. This update highlights Zimmer Biomet's focus on its core orthopedic implant business and its capital return policy for investors.
Barclays (DJP) sells $2.63M AutoCallable Contingent Coupon Notes, 9.70% p.a.
Barclays Bank PLC is offering $2.63 million in AutoCallable Contingent Coupon Notes, set to mature on May 23, 2029, with a contingent annual coupon rate of 9.70%. These notes are linked to the performance of four equity securities: BDX, GEHC, ZBH, and DHR, and investors' principal repayment at maturity is subject to the performance of the least performing reference asset. The offering includes potential risks such as loss of principal, dependence on Barclays' creditworthiness and the U.K. Bail-in Power, and limited upside potential compared to direct equity ownership.
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2026 Earnings Call Transcript
This article provides the Q1 2026 earnings call transcript for Zimmer Biomet Holdings, Inc. (ZBH). It highlights the company's strong financial performance, including a 5% revenue increase, improved gross margin, and a 20% rise in EPS, alongside a 25% increase in free cash flow. This positive outlook suggests a potential stock price increase of 2% to 8% in the near future.
Medtronic to spend $650M on 60-day nerve therapy for chronic pain
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash. This acquisition will add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, aiming to expand care options for chronic pain sufferers. The deal is expected to close in the first half of Fiscal 2027, subject to regulatory approvals.
North Dakota State Investment Board Buys Shares of 19,728 Edwards Lifesciences Corporation $EW
The North Dakota State Investment Board has acquired a new stake of 19,728 shares in Edwards Lifesciences Corporation, valued at approximately $1.68 million, during the fourth quarter. This move comes as Edwards Lifesciences reported strong quarterly results, exceeding analyst expectations with $0.78 EPS and $1.65 billion in revenue, driven by 16.7% year-over-year revenue growth. Analysts maintain a "Moderate Buy" consensus for the stock with a target price of $95.65, despite recent insider share sales.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of "Hold" from Analysts
Analysts have given Zimmer Biomet Holdings, Inc. (NYSE:ZBH) a consensus "Hold" rating, based on coverage from 23 research firms with an average 12-month price target of $102.80. The company recently exceeded earnings expectations, reporting a 9.3% year-over-year revenue increase and raising its FY2026 EPS guidance. Zimmer Biomet also continues to reward shareholders with a quarterly dividend of $0.24 per share, representing an annual yield of approximately 1.1%.
Gabelli Funds LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Gabelli Funds LLC increased its stake in Zimmer Biomet Holdings, Inc. by 12.4% in the fourth quarter, bringing its total to 130,350 shares valued at $11.7 million. Zimmer Biomet reported stronger-than-expected quarterly results, with $2.09 EPS on revenue of $2.09 billion, up 9.3% year-over-year. While analyst sentiment is mixed with an average "Hold" rating and a price target of $102.80, the company recently announced a quarterly dividend of $0.24 per share.
Suketu Upadhyay sells 31,253 ZBH shares (NYSE: ZBH)
Suketu Upadhyay filed a Form 144 to disclose a proposed sale of 31,253 shares of Zimmer Biomet Holdings, Inc. (ZBH) common stock, valued at $2,608,859.38, with a sale date of May 12, 2026. This filing indicates an insider's intent to sell shares and lists previous equity events such as restricted stock vesting and an ESPP purchase. The document is a disclosure of intent under resale rules, and it does not detail the exact sale mechanics or cash-flow recipients.
Robotics expert Brian Miller on product development, AI and what he learned at Intuitive
Brian Miller, former Intuitive EVP and chief digital officer, shares insights on product development, understanding customer needs, and the role of AI in surgical robotics, drawing from his extensive experience. Now CEO of Sovato, Miller emphasizes the importance of critical thinking, deep customer observation, and responsible use of AI and data in medical device innovation. He also touches on making the most of intraprocedural data and addressing potential "deskilling" concerns with advanced technologies.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 1.10% to $86.08 on Tuesday, outperforming the broader market during a dismal trading session. The S&P 500 Index and Dow Jones Industrial Average both experienced declines, while ZBH recorded its third consecutive day of gains.
Is Enovis’ Improving Q1 2026 Results And Reaffirmed Outlook Altering The Investment Case For ENOV?
Enovis Corporation reported improving Q1 2026 results with reduced net loss and reaffirmed its 2026 revenue outlook of US$2.31 billion to US$2.37 billion. This indicates progress in operational performance and management confidence, despite historical losses and complexities from acquisitions. The article suggests these developments support the near-term catalyst of better execution, but investors should remain aware of ongoing integration challenges and potential delays.
Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Independent Advisor Alliance
Independent Advisor Alliance significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 85.5% in the fourth quarter. Despite this, Zimmer Biomet reported strong quarterly results, beating analyst estimates for EPS and revenue, and institutional investors collectively own 88.89% of the company's stock. The company also announced a quarterly dividend and analysts currently have a "Hold" rating with an average target price of $102.80.
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock rises By Investing.com
NeuroOne Medical Technologies Corporation reported Q2 FY2026 earnings per share and revenue below analyst forecasts, with an EPS of -$0.25 against -$0.22 expected and revenue of $2.4 million versus $2.58 million. Despite these misses, the company's stock rose by 4.16% due to strong product revenue growth of 72% year-over-year and investor optimism regarding strategic initiatives and product innovations. The call highlighted significant progress in its OneRF Brain Ablation and Trigeminal Nerve Ablation systems, ongoing drug delivery program, and plans for international expansion, although liquidity concerns stemming from declining cash reserves were noted.
A Look At Zimmer Biomet (ZBH) Valuation After 2026 Buyback Boost And Higher EPS Guidance
Zimmer Biomet Holdings (ZBH) has announced an increase in its 2026 share repurchase expectations to US$1.0 billion and raised its adjusted earnings per share forecast, leading to recent positive share price movement despite a weaker year-long performance. The stock, currently trading at US$83.70 with an estimated intrinsic value of US$102.95, is considered undervalued, driven by expectations of improved sentiment and future growth from strategic investments in digital health and robotics. However, potential risks like flat pricing and integration challenges could impact margins.
New Philips heart imaging cuts X-ray dose by over half in complex procedures
Philips will present new imaging, physiology, and AI-enabled guidance solutions at EuroPCR 2026, aimed at reducing X-ray radiation doses by over 50% in complex coronary and structural heart procedures. Key innovations include SmartIQ technology, IntraSight Plus, and DeviceGuide, designed to improve workflow efficiency and patient care while minimizing radiation exposure for both patients and staff. The company emphasizes integrated solutions to manage procedural complexity without compromising image quality or clinical confidence.
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
This article compares Abbott (ABT) and Zimmer Biomet (ZBH), two major players in the surgical equipment market, to determine which is a better investment. While Abbott is a larger, more diversified healthcare company, Zimmer Biomet has shown stronger year-to-date performance and more attractive valuation. The analysis suggests that Zimmer Biomet presents a stronger investment case at this time due to rising earnings projections and recent strategic successes.
Northwestern Mutual Wealth Management Co. Purchases 1,093,692 Shares of Edwards Lifesciences Corporation $EW
Northwestern Mutual Wealth Management Co. significantly increased its stake in Edwards Lifesciences Corporation by 1,952.7%, acquiring an additional 1,093,692 shares, bringing its total holdings to 1,149,700 shares valued at approximately $98.0 million. The medical research company recently reported strong earnings, beating analyst expectations with 16.7% year-over-year revenue growth. Despite this positive financial performance and largely favorable analyst ratings, Edwards Lifesciences has seen notable insider selling, with a CFO and VP selling a combined 88,096 shares in the last 90 days.
Q1 Earnings Highs And Lows: STERIS (NYSE:STE) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks
This article analyzes the Q1 2026 earnings performance of STERIS (NYSE:STE) and its peers in the surgical equipment & consumables - diversified industry. While STERIS's revenue was in line with expectations, it showed the weakest performance against estimates among its peers. The report also highlights the strong performance of Zimmer Biomet (NYSE:ZBH), BD (NYSE:BDX), Solventum (NYSE:SOLV), and CONMED (NYSE:CNMD), noting their revenue figures and market reactions.
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35% - News and Statistics
Artivion's Q1 2026 earnings saw revenue of $116.3 million, matching analyst estimates, but adjusted EPS missed expectations by 35.1% at $0.08 versus $0.12. The company attributed the shortfall to weak stent graft sales and delays in AMDS starter set sales due to hospital procurement issues, leading to a downward revision in full-year revenue and EBITDA guidance. Analysts questioned management on the conservatism of the revised guidance and the impact of future PMA approval for AMDS.
Eubel Brady & Suttman Asset Management Inc. Decreases Position in Zimmer Biomet Holdings, Inc. $ZBH
Eubel Brady & Suttman Asset Management Inc. reduced its stake in Zimmer Biomet Holdings, Inc. by 6.6% in the fourth quarter of the prior year, selling 19,274 shares and now holding 273,475 shares valued at approximately $24.6 million. Zimmer Biomet's recent earnings exceeded expectations, reporting $2.09 EPS against a $1.86 consensus and revenue of $2.09 billion, increasing 9.3% year-over-year. Despite beating earnings, analyst sentiment remains a "Hold" with an average price target of $102.80, higher than the recent trading price of $83.73.
Hills Bank & Trust Co Sells 14,826 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Hills Bank & Trust Co significantly reduced its stake in Zimmer Biomet Holdings, Inc. by 64.9%, selling 14,826 shares and retaining 8,012 shares valued at $720,000. This divestment occurred despite Zimmer Biomet reporting better-than-expected Q4 earnings with an EPS of $2.09 against estimates of $1.86, and revenue of $2.09 billion, increasing 9.3% year-over-year. Analysts remain cautious, holding an average "Hold" rating with a consensus price target of $102.80, and several firms recently trimmed their price targets.
Helios Technologies Shares Surge 12.5% After Strong Q1 2026 Earnings
Helios Technologies (NYSE:HLIO) shares climbed 12.5% following its Q1 2026 earnings report, which exceeded Wall Street expectations. The company reported a 16.8% year-over-year revenue increase to $228.4 million and adjusted EPS of $0.80, beating estimates. Management subsequently raised its full-year revenue and adjusted EPS guidance, indicating a positive market reaction to the strong performance and recent product expansion into the data center market.
Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?
Fractyl Health (GUTS) saw a 14.0% stock increase following its Q1 2026 profitability shift to $9.22 million net income and authorization to begin human trials for its RJVA-001 GLP-1 gene therapy in the Netherlands. This development makes Fractyl a dual clinical-stage company, alongside its Revita procedure for weight maintenance. While the RJVA-001 authorization strengthens the long-term Rejuva gene therapy story, the Revita data and potential FDA filing in late 2026 remain the more immediate catalysts for the company.
Analysts Have Made A Financial Statement On Shoulder Innovations, Inc.'s (NYSE:SI) First-Quarter Report
Shoulder Innovations, Inc. (NYSE:SI) saw its shares surge 18% after its first-quarter report, with revenues of US$17m beating expectations. Analysts have updated their forecasts, projecting 2026 revenues of US$67.3m, a 25% improvement, and a reduction in losses to US$1.70 per share, despite a modest increase in loss per share forecasts. The consensus price target remained unchanged at US$21.25, indicating that growing revenues offset concerns about increasing losses.
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors
This article from MSN indicates that Zimmer Biomet Holdings Inc. (ZBH) stock underperformed on Tuesday relative to its competitors. The provided content is extremely brief, offering no further details on the extent or reasons for this underperformance.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 1.27% to $83.70 on Friday, despite a negative trading day for the broader market. The S&P 500 Index (SPX) fell 1.24% and the Dow Jones Industrial Average (DJIA) fell 1.07%. This gain broke a two-day losing streak for Zimmer Biomet Holdings Inc.
What Are Wall Street Analysts' Target Price for Zimmer Biomet Stock?
Zimmer Biomet Holdings, Inc. (ZBH) has underperformed the broader market, with its stock decreasing 13.6% over the past 52 weeks and 7.1% YTD. Despite reporting stronger-than-expected Q1 2026 earnings and raising EPS guidance, the stock tumbled after the CFO's unexpected departure and firm revenue guidance. Analysts currently have a "Hold" consensus rating for ZBH, with a mean price target of $98.81, indicating a 17.5% potential upside from current levels.
T. Rowe Price reports 4.1% stake in Zimmer Biomet (NYSE: ZBH) amendment
T. Rowe Price Associates, Inc. has filed an amendment (Schedule 13G/A) disclosing a 4.1% beneficial ownership stake in Zimmer Biomet Holdings Inc. (NYSE: ZBH). The filing indicates that T. Rowe Price beneficially owns 7,997,806 shares of common stock, with sole voting power over 7,523,342 shares and sole dispositive power over all 7,997,806 shares. The report period for this amendment is March 31, 2026, and it was signed on May 15, 2026.
Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, reflecting institutional confidence. This increased investment follows strong quarterly results from Zimmer Biomet, which exceeded revenue and EPS estimates. Despite the positive performance, Wall Street analysts currently maintain a "Hold" rating on the stock, with an average target price of $102.80.
Can ISRG's da Vinci 5 Momentum Sustain Procedure and Utilization Gains?
Intuitive Surgical's new da Vinci 5 platform is proving to be a significant growth driver, enhancing procedure momentum and system utilization. The platform's superior ergonomics and technology are leading to higher utilization rates compared to previous models, which could increase recurring revenue. Additionally, a rise in after-hours procedures suggests more intensive use of existing systems, strengthening the economic value proposition for hospitals.
Zimmer Biomet stock (US98956P1021): Leading medical device maker with strong US market presence
Zimmer Biomet is a leading medical device maker specializing in orthopedic implants and surgical solutions, with a strong presence in the US market, driven by an aging population and high demand for joint replacements. The company reported full-year 2025 revenue of $7.6 billion, showing significant growth, largely due to its strong domestic performance. Zimmer Biomet focuses on innovation, investing in robotic-assisted surgery and smart implant technologies to maintain its competitive edge in the growing global orthopedics market.
Pacer Advisors Inc. Has $62.74 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Pacer Advisors Inc. significantly increased its stake in Zimmer Biomet Holdings, Inc. during the fourth quarter, now holding 697,753 shares valued at $62.7 million. Zimmer Biomet recently reported strong quarterly earnings, surpassing analyst estimates, but analysts maintain a cautious "Hold" rating with a consensus price target of $102.80. The company's stock currently trades at $82.67, with institutional investors owning a substantial portion of its shares.
Stryker Corp stock (US8636671013): Medical technology leader with strong US market presence
Stryker Corp is highlighted as a leading medical technology company, innovating in orthopedics, medsurg, and neurotechnology. The article emphasizes its strong market presence in the US, with a significant revenue base from US hospitals. Stryker's robust financial performance in Q1 2026, driven by its diversified product portfolio and strategic acquisitions, positions it well within the growing global medical devices market.
Surgical Robotics Market to Reach USD 16.89 Billion by 2033 as
The global surgical robotics market, valued at US$ 6.60 billion in 2025, is projected to hit US$ 16.89 billion by 2033, growing at an 11.3% CAGR. This growth is fueled by increasing demand for minimally invasive surgeries, technological advancements, and the rising prevalence of chronic diseases. North America currently leads the market with a 40% share, while Asia-Pacific is rapidly emerging as a fast-growing region.
Osteonecrosis Treatment Market Key Players | Novartis AG, Zimmer Biomet, Exactech, Inc., Merck & Co. Inc. etc.
The Osteonecrosis Treatment Market is projected to grow from US$ 637.18 million in 2022 to US$ 1,021.92 million by 2030, driven by early diagnosis, advanced biologics, and improved surgical outcomes. Key drivers include the rising prevalence of bone disorders, demand for minimally invasive procedures, and advancements in regenerative medicine. The market is highly competitive, with a focus on strategic collaborations and R&D, and faces challenges such as high treatment costs and complex regulatory pathways.
Zimmer Biomet Holdings | 10-K: FY2025 Annual Report
This entry is a 10-K Annual Report filing forzimmer Biomet Holdings for the fiscal year 2025. It indicates that the document itself contains the full financial and operational details for the company during that period.
Smith & Nephew stock (GB0009223206): sets sterling final dividend ahead of May payout
Smith & Nephew plc has confirmed the sterling equivalent of its 24.1 US cents final dividend for 2025, payable on May 27, 2026, to shareholders of record by March 27, 2026. Eligible UK shareholders will receive 17.78 pence per share. The company, a global medical technology firm, emphasizes innovation in orthopaedics, sports medicine, ENT, and advanced wound management.
Is There Now An Opportunity In Enovis (ENOV) After Multi Year Share Price Slump
Enovis (ENOV) stock has seen significant declines over the past few years but shows signs of being undervalued according to Simply Wall St's analysis. A Discounted Cash Flow (DCF) model suggests a 53.5% discount to its estimated intrinsic value, and its Price-to-Sales (P/S) ratio is well below industry averages. Investors might find an opportunity given these valuation metrics, despite the prolonged share price slump.
NeuroOne Medical Technologies Corp (NMTC) Q2 2026 Earnings Call
NeuroOne Medical Technologies Corp (NMTC) reported strong product revenue growth of 72% year-over-year for its 1RF brain ablation system in Q2 2026, reaching $2.4 million. Despite regaining Nasdaq compliance and advancing international certification and strategic partnerships, the company faces challenges with profitability, cash flow, and a lack of license revenue compared to the previous year. The net loss for the quarter was $2.1 million, and cash equivalents decreased, while the commercialization strategy for its drug delivery platform and facial pain system is still developing.
Fidelity records proposed sale of ZBH common shares (ZBH)
A Form 144 SEC filing from Zimmer Biomet Holdings, Inc. (ZBH) indicates proposed sales of common stock through Fidelity Brokerage Services LLC. These sales originate from employee stock purchase plan (ESPP) acquisitions and restricted stock vesting events recorded up to May 12, 2026. The filing details multiple share amounts and dates, highlighting Fidelity as the broker.
Smith & Nephew stock (GB0009223206): Bernstein cuts price target after Q1 update
Bernstein has lowered its price target for Smith & Nephew (GB0009223206) following the company's Q1 trading update. Despite the price target cut, Smith & Nephew confirmed its final dividend for 2025 at 17.78 pence per share, payable on May 27, 2026. The medical device maker, listed on NYSE and LSE, specializes in orthopedics, sports medicine, and wound care, with over half its sales coming from the US market.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Zimmer Biomet Holdings Inc. (ZBH) saw its stock increase by 4.76% to $83.37, outperforming a mixed stock market day. This rise ended a two-day losing streak for the company. The Dow Jones Industrial Average rose slightly, while the S&P 500 Index experienced a minor decline.
NeuroOne Medical Tech Q2 2026 Earnings Call Transcript
NeuroOne Medical Technologies Corp (NASDAQ: NMTC) reported a 72% year-over-year increase in product revenue for its One RF brain ablation system, reaching $2.4 million in Q2 2026. The company announced key executive transitions, regained NASDAQ compliance, and secured a new high-net-worth investor, while also making progress on international distribution and clinical trials for new systems. Moving forward, NeuroOne expects continued expansion of its ablation systems and the commercial availability of its drug delivery system in the second half of fiscal 2026, alongside ongoing development in back pain technologies.
Zimmer Biomet Expands 2026 Share Repurchase Program
Zimmer Biomet Holdings (ZBH) has increased its expected share repurchases for fiscal 2026 by $250 million, now planning to buy back up to $1 billion of common stock. This move, made under an existing $1.5 billion authorization, signals the company's confidence in its financial health and aims to enhance shareholder value through increased capital return. Despite weak technical positioning, the company maintains a solid financial base and positive earnings outlook according to TipRanks’ AI Analyst, Spark.
